Pharmamarketeer
AstraZeneca's Farxiga gets US FDA approval to reduce risk of CV death 
wet- en regelgeving

AstraZeneca’s Farxiga gets US FDA approval to reduce risk of CV death and hospitalisation for heart failure to a broader range of patients

10 mei 2023
Pharma Biz

AstraZeneca’s Farxiga gets US FDA approval to reduce risk of CV death

AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER phase III trial. Farxiga was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF).

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)